Safety Evaluation for a Cell-based Immune Support System in an Ex Vivo Rat Model of Gram-negative Sepsis

Granulocyte dysfunction is a central component of immunodeficiency in septic patients. Granulocyte transfusions appear to be pathophysiologically useful; however, they cause unwanted side‐effects in the lungs and other organs. This study evaluates the safety of an extracorporeal immune support syste...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic apheresis and dialysis 2009-10, Vol.13 (5), p.444-450
Main Authors: Sauer, Martin, Altrichter, Jens, Kreutzer, Hans-Jürgen, Schmidt, Heidrun, Nöldge-Schomburg, Gabriele, Schmidt, Reinhard, Mitzner, Steffen R
Format: Article
Language:English
Subjects:
Animals
Data processing
Disease Models, Animal
Endotoxins
Escherichia coli
Escherichia coli Infections - immunology
Escherichia coli Infections - therapy
Gram-Negative Bacterial Infections - immunology
Gram-Negative Bacterial Infections - therapy
Granulocytes - immunology
Granulocytes - transplantation
Hemodynamics
HL-60 Cells
Human promyelocytic leukemia cell line
Humans
Immune support system
Immunodeficiency
Leukocytes (granulocytic)
Lung
Male
Neutrophil
Phagocytosis
Promyeloid leukemia
Rat model
Rats
Rats, Inbred Strains
Sepsis
Sepsis - immunology
Sepsis - microbiology
Sepsis - therapy
Side effects
Survival Rate
Transfusion
Tumor cell lines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Granulocyte dysfunction is a central component of immunodeficiency in septic patients. Granulocyte transfusions appear to be pathophysiologically useful; however, they cause unwanted side‐effects in the lungs and other organs. This study evaluates the safety of an extracorporeal immune support system with granulocytic cells in a rat model of Gram‐negative sepsis. Three groups of male CD rats received either saline (control group, I), a dose of Escherichia coli O7:K1 lethal to 90% of the animals (LD90) (septic group, II), or an LD90 dose of E. coli that was incubated with the human promyelocytic leukemia cell line (HL‐60) (differentiated into the granulocytic direction) for 20 min prior to infusion (second septic group, III). The animals were observed for seven days. Pre‐treatment with HL‐60 cells resulted in no adverse effects in the group III animals. Significantly lower bacterial counts and endotoxin levels in the plasma were detected after 24 h as compared to group II (P 
ISSN:1744-9979
1744-9987
DOI:10.1111/j.1744-9987.2009.00764.x